DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 177 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q1 2024. The put-call ratio across all filers is 5.21 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $83,316,194 | +7.6% | 5,296,643 | +10.3% | 3.06% | +10.4% |
Q4 2023 | $77,448,840 | +36.0% | 4,801,540 | +7.3% | 2.77% | +2.3% |
Q3 2023 | $56,926,884 | -17.1% | 4,475,384 | -8.3% | 2.71% | +2.8% |
Q2 2023 | $68,690,209 | -20.4% | 4,878,566 | -12.6% | 2.64% | -29.6% |
Q1 2023 | $86,243,522 | +46.4% | 5,582,105 | +55.3% | 3.74% | +55.3% |
Q4 2022 | $58,894,466 | +7.1% | 3,593,317 | +20.9% | 2.41% | +12.9% |
Q3 2022 | $55,001,000 | +192.3% | 2,973,029 | +107.8% | 2.13% | +196.7% |
Q2 2022 | $18,817,000 | +205.3% | 1,430,917 | +115.2% | 0.72% | +274.5% |
Q1 2022 | $6,163,000 | -5.1% | 664,817 | 0.0% | 0.19% | +29.7% |
Q4 2021 | $6,495,000 | -95.3% | 664,817 | -83.5% | 0.15% | -93.8% |
Q3 2021 | $136,991,000 | -11.8% | 4,031,521 | -5.0% | 2.39% | +3.9% |
Q2 2021 | $155,399,000 | -20.4% | 4,244,721 | -2.5% | 2.30% | -16.3% |
Q1 2021 | $195,128,000 | -23.0% | 4,351,644 | -1.9% | 2.75% | -10.4% |
Q4 2020 | $253,275,000 | +3.4% | 4,437,968 | -7.1% | 3.07% | -31.8% |
Q3 2020 | $244,953,000 | -17.6% | 4,774,918 | -4.1% | 4.50% | -18.1% |
Q2 2020 | $297,342,000 | +41.2% | 4,978,941 | -2.7% | 5.49% | -7.0% |
Q1 2020 | $210,637,000 | -28.1% | 5,116,263 | +8.6% | 5.90% | -15.8% |
Q4 2019 | $293,119,000 | +80.6% | 4,709,498 | -1.5% | 7.01% | +29.1% |
Q3 2019 | $162,264,000 | +223.6% | 4,780,898 | +115.0% | 5.43% | +282.7% |
Q2 2019 | $50,137,000 | +32.6% | 2,223,376 | +36.5% | 1.42% | +28.3% |
Q1 2019 | $37,801,000 | +8.9% | 1,628,653 | -1.5% | 1.11% | -20.8% |
Q4 2018 | $34,700,000 | -39.3% | 1,653,180 | +12.0% | 1.40% | -20.6% |
Q3 2018 | $57,173,000 | -1.6% | 1,476,580 | -0.0% | 1.76% | -10.9% |
Q2 2018 | $58,123,000 | +253.2% | 1,477,080 | +79.9% | 1.97% | +210.4% |
Q1 2018 | $16,458,000 | +12.3% | 821,280 | +20.1% | 0.64% | -0.2% |
Q4 2017 | $14,658,000 | +22.6% | 683,880 | -5.4% | 0.64% | +8.0% |
Q3 2017 | $11,957,000 | – | 722,880 | – | 0.59% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
New Leaf Venture Partners, L.L.C. | 1,209,571 | $15,385,743 | 19.76% |
Redmile Group, LLC | 4,475,384 | $56,926,884 | 2.71% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 6,897,606 | $87,737,548 | 1.93% |
Parkman Healthcare Partners LLC | 597,403 | $7,598,966 | 1.39% |
Ghost Tree Capital, LLC | 325,000 | $4,134,000 | 1.36% |
BRAIDWELL LP | 3,336,221 | $42,436,731 | 1.34% |
AlphaCentric Advisors LLC | 132,000 | $1,679,040 | 0.95% |
ARMISTICE CAPITAL, LLC | 4,612,000 | $58,664,640 | 0.90% |
Sunesis Advisors, LLC | 96,299 | $1,224,923 | 0.87% |
EcoR1 Capital, LLC | 993,000 | $12,630,960 | 0.43% |